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ABSTRACT
Meningiomas are the most common primary intracranial adult tumor. All 
Neurofibromatosis 2 (NF2)-associated meningiomas and ~60% of sporadic 
meningiomas show loss of NF2 tumor suppressor protein. There are no effective 
medical therapies for progressive and recurrent meningiomas. Our previous work 
demonstrated aberrant activation of mTORC1 signaling that led to ongoing clinical 
trials with rapamycin analogs for NF2 and sporadic meningioma patients. Here we 
performed a high-throughput kinome screen to identify kinases responsible for 
mTORC1 pathway activation in NF2-deficient meningioma cells. Among the emerging 
top candidates were the mTORC2-specific target serum/glucocorticoid-regulated 
kinase 1 (SGK1) and p21-activated kinase 1 (PAK1). In NF2-deficient meningioma 
cells, inhibition of SGK1 rescues mTORC1 activation, and SGK1 activation is sensitive 
to dual mTORC1/2 inhibitor AZD2014, but not to rapamycin. PAK1 also leads to 
attenuated mTORC1 but not mTORC2 signaling, suggesting that mTORC2/SGK1 
and Rac1/PAK1 pathways are independently responsible for mTORC1 activation in 
NF2-deficient meningiomas. Using (CRISPR)-Cas9 genome editing, we generated 
isogenic human arachnoidal cell lines (ACs), the origin cell type for meningiomas, 
expressing or lacking NF2. NF2-null CRISPR ACs recapitulates the signaling of NF2-
deficient meningioma cells. Interestingly, we observe increased SGK1 transcription 
and protein expression in NF2-CRISPR ACs and in primary NF2-negative meningioma 
lines. Moreover, we demonstrate that the dual mTORC1/mTORC2 inhibitor, AZD2014 
is superior to rapamycin and PAK inhibitor FRAX597 in blocking proliferation of 
meningioma cells. Importantly, AZD2014 is currently in use in several clinical trials 
of cancer. Therefore, we believe that AZD2014 may provide therapeutic advantage 
over rapalogs for recurrent and progressive meningiomas.
INTRODUCTION
Neurofibromatosis 2 (NF2) is characterized by 
multiple nervous system tumors, including bilateral 
vestibular schwannomas, intracranial meningiomas, 
and spinal tumors such as schwannomas, meningiomas 
and ependymomas [1, 2]. Although most meningiomas 
are benign (WHO grade I), they often cause severe 
neurologic morbidity and mortality due to compression 
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of the adjacent brain or spinal cord. Benign meningiomas 
have recurrence rates of up to 20% over 10 years. Twenty 
percent of meningiomas are classified as atypical (WHO 
grade II) or anaplastic (WHO grade III), and display 
more aggressive clinical behavior with faster growth and 
increased recurrence rates [3, 4]. The current standard of 
care for NF2-related meningiomas is maximal surgical 
resection with adjuvant radiation reserved for inoperable 
or progressive tumors, or those with aggressive features 
(e.g., WHO grades II or III). Meningiomas that progress 
despite surgery and radiation cause high morbidity, and the 
overall NF2 patient survival rate is ~38% at 20 years from 
diagnosis [5]. Therefore, effective non-invasive therapies 
are much needed for NF2-associated meningiomas 
and vestibular schwannomas, as well as their sporadic 
counterparts commonly seen in the general population.
The NF2 tumor suppressor protein merlin (NCBI 
definition, Neurofibromin 2/NF2) has been implicated 
in a wide range of mitogenic signaling pathways [6] in 
various cell types. However, the mechanism by which 
merlin/NF2 loss in human arachnoidal and Schwann cells 
results in meningiomas and schwannomas remains poorly 
understood. Employing patient-derived NF2-deficient 
meningioma cells and NF2 knockdown (shRNA) human 
arachnoidal cells, the cell of origin for meningiomas, 
we established that mammalian/mechanistic target of 
rapamycin complex 1 (mTORC1) is negatively regulated 
by merlin/NF2. mTORC1 is constitutively activated in 
NF2-associated schwannomas and meningiomas, and 
rapamycin was shown to block this mTORC1 activation 
[7, 8]. Subsequent studies carried out in mouse models 
reported that rapamycin suppressed the growth of 
meningiomas in a xenograft model [9] and delayed the 
growth of NF2-related Schwann cell tumorigenesis [10]. 
These studies led to clinical trials with mTORC1 inhibitor 
everolimus (RAD001), a rapamycin analog, for NF2 and 
sporadic meningiomas. Initial results from these clinical 
trials have been mixed, with one study reporting no 
shrinkage of vestibular schwannomas during everolimus 
treatment [11], and other studies reporting a delay in 
vestibular schwannoma growth during treatment [10, 12].
mTOR is an evolutionarily conserved serine/
threonine kinase that regulates cell growth, proliferation 
and survival through two distinct functional complexes, 
mTORC1 and mTORC2, which signal to specific 
downstream targets [13, 14]. To further understand the 
role of merlin/NF2 in mTORC1 activation, we undertook 
an unbiased kinome screen in NF2-null meningioma 
cells. Here we report distinct activation of the mTORC2 
target SGK1, detected by phosphorylation of its substrate 
NDRG1 (N-myc downstream-regulated 1) in NF2-null 
human meningioma cells and NF2-deficient human 
arachnoidal cells, which remains insensitive to the 
mTORC1-specific inhibitor rapamycin. We further show 
that the selective mTOR kinase inhibitor AZD2014, 
targeting both mTORC1 and mTORC2, is more efficient 
than rapamycin in blocking proliferation of primary 
human meningioma cells and thus may hold promise as a 
more effective therapeutic option for NF2 patients.
RESULTS
High-throughput shRNA kinome screen reveals 
candidate kinases for constitutive mTORC1 
activation in NF2-deficient cells
We previously reported constitutive activation of 
mTORC1 signaling in NF2-deficient human arachnoidal 
cells (ACs), in primary meningioma cells and in NF2-
associated tumors, meningiomas and schwannomas. We 
placed NF2 upstream of the tuberous sclerosis complex 
proteins TSC1-TSC2, which inhibits mTORC1 through 
TSC2 GAP activity toward the small GTPase Rheb. Our 
results showed that NF2 negatively regulates mTORC1 
independent of PI3K/Akt and MEK/ERK pathways [7]. 
To further understand mTORC1 activation upon NF2 
loss, we raised the question whether Rheb is required for 
this activation, and observed that suppression of Rheb 
rescues the constitutive activation of mTORC1 signaling 
by immunofluorescence and immunoblotting analyses 
(Figure 1), which confirmed that NF2 loss results in 
mTORC1 activation in a Rheb-dependent manner. Next 
we undertook an immunofluorescence-based, high-
throughput kinome screen to identify kinases which, 
when suppressed, leads to decreased pathway activation 
using phosphorylated ribosomal S6 protein S240/244 
(pS6) as a readout (assessed by decreased pS6 staining 
intensity). The primary screen was carried out in triplicate 
in the NF2-negative benign meningioma cell line Ben-
Men-1 [15], using a high-titer lentiviral kinome shRNA 
library developed by The RNAi Consortium (TRC; 
Broad Institute/MIT, Cambridge, MA). Top hit calling 
was performed using robust z scoring methodology that 
is frequently employed in high-throughput RNAi screens 
to identify positives [16]. A list of top hit candidates 
emerged using the following criteria: 1) an infection 
efficiency > 60%, 2) two or more independent hairpins 
for an individual kinase displaying a robust z score < 
-1.8 (representing a reduction in pS6 staining intensity 
by >50% in our screen) observed in 3 replicates, and 3) 
no significant decrease in nuclei number to ensure that 
decreased pS6 was not due to decreased cell number. 
A secondary screen of independently packaged and 
assembled shRNA lentivirus (5 hairpins/candidate) 
for top hits in Ben-Men-1 cells confirmed the primary 
screen candidates. As predicted, mTOR emerged as a 
significant kinase with an average robust z score of -2.30 
for 3 independent shRNA clones, thus showing proof-
of-concept for the screen. Interestingly, two top kinases 
to emerge were serum/glucocorticoid-regulated kinase 1 
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Figure 1: Constitutive mTORC1 activation in NF2-deficient meningioma cells is Rheb-dependent. A. Immunoblotting 
of NF2-deficient meningioma cell line BenMen1 shows attenuated pS6 (mTORC1 readout) upon transduction of lentiviral Rheb shRNA 
compared to control (nullT) shRNA, under serum-deprived conditions. NF2 expression is shown compared to normal arachnoidal cell 
(AC) line. S6 serves as a control. B. Immunofluorescence staining of Benmen1 cells, transduced with lentiviral Rheb-shRNA (right panel), 
reveals significant attenuation of pS6-Alexa488 (green) staining compared to nullT-shRNA control (left panel). DAPI staining (blue) of 
cell nuclei is shown. Scale bar = 100µm. 
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(SGK1) and p21 protein-activated kinase 1 (PAK1). SGK1 
and PAK1 were each identified by 2 independent shRNA 
clones in triplicate with robust z scores of -2.47 and -2.28, 
respectively (Figure 2, Table 1).
SGK1 is one of three primary downstream AGC 
kinase targets of mTORC2, which also include Akt and 
PKC [17-19]. Previously Huang et al. demonstrated that 
Tsc2-deficient mouse embryonic fibroblasts (MEFs) with 
constitutive activation of mTORC1 revealed inhibition of 
mTORC2 activity with attenuated phosphorylation of all 
three targets Akt, PKC-α and SGK1, using the effector 
pNDRG1 as a biomarker for SGK1 activation [20]. In 
contrast, we recently demonstrated that in NF2-shRNA 
suppressed human ACs and Schwann cells (SCs), while 
like Tsc2-/- MEFS show attenuated pAkt and pPKC-α, 
the mTORC2 target SGK1/pNDRG1 displays robust 
constitutive activation [21]. Regarding PAK1, NF2 
protein is known to negatively regulate Rac1 signaling 
via inhibition of PAK1, and it has been demonstrated 
that loss of Nf2 expression leads to activation of Pak1 in 
rat Schwann cells [22, 23]. In addition, PAK1 activity is 
upregulated in NF2 patient-derived schwannomas [24]. 
Moreover, chemical compounds targeting PAK1 have 
been suggested as a potential therapeutic for NF2 [25, 
26]. Given our recent observation of mTORC2-SGK1/
pNDRG1 activation in NF2-deficient cells [21], as well 
as reports associating NF2 with Rac1/PAK1 signaling, we 
chose to follow up and expand our studies of these two 
candidate kinases.
NF2-deficient cells show activation of SGK1/
pNDRG1, and SGK1 inhibition rescues 
constitutive mTORC1/pS6 activation
Of the two independent SGK1-shRNA clones that 
rescued pS6 activation in our screen, we performed large-
scale packaging of 1 clone to carry out further studies. 
Inhibition of SGK1 was performed using lentiviral 
SGK1-shRNA infection in Ben-Men-1 cells, or with the 
SGK1 inhibitor GSK650394 in both Ben-Men-1 cells and 
NF2-shRNA ACs. Both of these showed attenuation of 
mTORC1 signaling (pS6 readout) and downregulation of 
pNDRG1, a specific readout for SGK1 activation (Figure 
3A and 3B). Importantly, while many recent studies 
demonstrate SGK1 as a downstream target of mTORC2 
signaling, SGK1 has also been reported downstream of 
mTORC1 in some cell types [27]. We tested whether 
Table 1: Top candidate kinases identified in the high-throughput shRNA kinome screen
Gene ID # shRNAs robust z score2  Protein description
LMTK3 3 -2.57  lemur tyrosine kinase 3 
SGK1 2 -2.47  serum/glucocorticoid-regulated kinase 1 
ALPK2 2 -2.47  alpha kinase-2 
OBSCN 2 -2.51  obscurin, cytoskeletal calmodulin and titin-interacting Rho-GEF
CRKL 2 -2.33  oncogene CRK-like; v-CRK avian sarcoma virus CT10-homolog-like 
MTOR 3 -2.30  mammalian/mechanistic target of rapamycin 
PAK1 2 -2.28  p21 protein-activated kinase 1 
GRK7 2 -2.20  G protein coupled receptor kinase 7
ERBB3 3 -2.17  V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 3
EPHA5 2 -2.12  ephrin receptor EphA5 
RHEB1 n/a -2.00  Rheb-GTPase, shRNA control
nullT1 n/a 0.49  non-hairpin forming negative control
GFP1 n/a 0.12  negative control hairpin control
1 positive and negative controls used on every plate
2 average robust z score from 3 replicates of each candidate hairpins
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the observed constitutive SGK1/pNDRG1 activation 
was blocked by either mTORC1 inhibition alone or dual 
inhibition of mTORC1/mTORC2 signaling. We treated 
NF2-shRNA ACs and Ben-Men-1 cells with the allosteric 
mTORC1 inhibitor, rapamycin, or an ATP-competitive 
dual mTORC1/2 kinase inhibitor, Torin1. In both cellular 
models, we observed downregulation of SGK1/pNDRG1 
with Torin1 treatment; however, pNDRG1 was not rescued 
in NF2-suppressed ACs using rapamycin (Figure 3C 
compared to 3D). This suggests that SGK1 activation is 
dependent on mTORC2 and independent of mTORC1. 
Inhibition of PAK1 rescues constitutive mTORC1 
signaling but not mTORC2-SGK1/pNDRG1 in 
NF2-deficient cells
In our high-throughput screen we identified two 
independent shRNA clones targeting PAK1 that rescued 
the constitutive mTORC1 activation in Ben-Men-1 cells 
(Table 1), and we performed large-scale packaging of 
1 clone to carry out further studies. Inhibition of PAK1 
using lentiviral PAK1-shRNA infection or treatment using 
the group I PAK inhibitor FRAX597 in Ben-Men-1 cells 
showed attenuation of pS6 (Figure 4A and 4B). FRAX597 
treatment resulted in a dose-dependent decrease of pS6 
and downregulation of pPAK1 S144 (Figure 4B and 
4C). We also carried out shRNA suppression of RAC1 
which also attenuated mTORC1/pS6; however, PAK1-
shRNA, RAC1-shRNA and FRAX597 inhibitor treatment 
were unable to rescue constitutive activation of SGK1/
pNDRG1, suggesting PAK1 and RAC1 are not required 
for activation of SGK1/pNDRG1, and may play a distinct 
role for constitutive mTORC1 activation in these cells 
(Figure 4A and 4C).
NF2-null CRISPR ACs shows activation of 
mTORC1 and mTORC2/SGK1 signaling
NF2-shRNA knockdown ACs show significant 
reduction, but not total absence of NF2; therefore, we 
employed CRISPR-Cas9 genome editing using a single 
guide RNA targeting the human NF2 exon 8 [28] in 
AC007-hTERT. Genotyping of selected single clones 
revealed 6 clones retaining wildtype (WT) sequence for 
NF2 exon 8, 3 clones with homozygous NF2 exon 8 in/
del mutations, and 3 clones with compound heterozygous 
NF2 exon 8 in/dels with distinct mutations on each allele, 
where all in/del mutations predicted putative premature 
stop codons. We chose independent clones of NF2-
expressing ACs (clones A2(+) and A3(+), WT) and NF2-
null CRISPR ACs (clones A4(-) and A17(-), compound 
het; and A19(-), homozygous) (Table 2) and tested the 
Figure 2: High-throughput kinome shRNA screen reveals kinases that rescue constitutive mTORC1 activation 
in NF2-deficient human meningioma cells. Ten kinases with an average robust z score of  <  -1.8 were identified by reduced 
immunofluorescence staining of pS6 (S240/244) (mTORC1 readout) after infection of Ben-Men-1 cells with individual kinase shRNAs. 
Each spot represents an average of 3 replicates, with  >  2 hairpins for each top hit shown (encircled black triangles).
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Table 2:  Isogenic, clonally-derived lines generated from an immortalized arachnoid cell line using CRISPR-Cas9 
genome editing
clone ID1 NF2 expression NF2 (ex8) mutation
2
A2 +  wildtype
A3 +  wildtype
A4 -
 compound heterozygous alleles
 1) 787del23bp, 263fs > 274X
 2) 804insC, 269fs > 275X
A17 -
 compound heterozygous alleles
 1) 795del8bp, 265fs > 274X 
 2) 802insT, 268fs > 274X
A19 -  homozygous 787del35bp, E8/I8 
1 ID numbers for NF2-expressing (+) and NF2-null (-) clones.
2 genotype for individual clones. 
Figure 3: SGK1 regulates mTORC1 signaling in an mTORC2-dependent manner. A. Immunoblot analysis with indicated 
antibodies of Ben-Men-1 cells treated with SGK1 inhibitor GSK650394 (2 µM, 18h; left panel) or SGK1-suppressed (shRNA, right panel) 
shows decreased SGK1 levels as well as attenuated NDRG1 (T346) phosphorylation (pNDRG1) and S6 (S240/244) phosphorylation (pS6) 
compared to DMSO treated or control shRNA, respectively. B. Immunoblotting with indicated antibodies of NF2-suppressed (shRNA) 
human arachnoidal cells (AC cells) treated with GSK650394 (0.5 - 2 µM) compared to DMSO (0) shows dose-dependent attenuation of 
constitutive pNDRG1 and pS6. Left panel, DMSO treated control ACs. C. Rapamycin treatment (20 nM, 2 h) of NF2 shRNA transduced 
ACs shows attenuation of pS6 but not pNDRG1 (SGK1 readout) compared to DMSO alone. D. In NF2-shRNA ACs or Ben-Men-1 cells, 
constitutive activation of both pNDRG1 and pS6 are attenuated upon treatment of with dual mTORC1/2 inhibitor Torin1 (250 nM, 1 h), 
compared to DMSO alone. NF2 expression levels are shown. NDRG1, S6 and GAPDH serve as controls. 
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direct effects of NF2 loss versus NF2 expression in these 
clones. All three NF2-null AC-CRISPR clones showed 
constitutive activation of mTORC1 signaling with 
enlarged cell morphology consistent with our earlier study 
with NF2-shRNA in these cells [7], as well as activation 
of SGK1 as detected by pNDRG1 compared to NF2-
expressing isogenic clones (Figure 5A and 5B). Consistent 
with our kinome screen results, SGK1-shRNA and SGK1 
inhibitor GSK650394, as well as the dual mTORC1/2 
kinase inhibitor AZD2014, inhibited pNDRG1 and pS6 in 
NF2-null CRISPR ACs under serum-deprived conditions 
(Figure 5C, left). In contrast, the Akt inhibitor AktVIII, 
while inhibiting insulin-stimulated pAkt S473 in NF2-
expressing ACs (Figure 5C, right), showed no effect on 
pNDRG1 or pS6 level in NF2-null CRISPR ACs (Figure 
5C, left). Akt activation was not observed in NF2-null 
Figure 4: PAK1 regulates mTORC1 signaling independent of mTORC2-SGK1. A. Immunoblotting of PAK1 shRNA Ben-
Men-1 cells with indicated antibodies reveals that PAK1-suppression attenuates pS6 with no change in pNDRG1 levels compared to control 
shRNA. B. Immunoblot analysis of Ben-Men-1 cells treated with the group I PAK inhibitor FRAX597 shows a dose-dependent decrease 
in constitutive pS6 compared to DMSO (0). C. Immunoblot analysis with indicated antibodies Ben-Men-1 cells treated with FRAX597 (2 
µM, 2h), or RAC1 shRNA reveals attenuation of both PAK1 (S144) phosphorylation (pPAK1, black arrowhead) and pS6, but no inhibition 
of pNDRG1 compared to control shRNA. Antibody for pPAK1 (S144) also detects pPAK2 (S141, gray arrowhead). NF2-expressing ACs 
serve as a control B. and C.. All experiments were carried out under serum-deprived conditions unless otherwise noted. 
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Figure 5: Inactivation of NF2 using CRISPR-Cas9 genome editing in human arachnoidal cells recapitulates enlarged 
cell morphology and signaling signatures of NF2-deficient human meningioma cells. A. Immunoblotting with indicated 
antibodies of NF2-null (-) AC-CRISPR clones compared with NF2-expressing (+) AC-CRISPR clones demonstrates loss of NF2 expression, 
increased p70S6K (T389) phosphorylation (pS6K) and pS6 (mTORC1 readouts), and increased pNDRG1 (SGK1 readout) compared with 
NF2-expressing (+) clones. S6K, S6 and NDRG1 serve as controls. B. Representative bright-field images show enlarged cell morphology 
in NF2-null (A17) AC-CRISPR clone (right) compared to NF2-expressing (A3) clone (left). Scale bar = 100 µm. C. Left panel shows 
immunoblot analysis with indicated antibodies of an NF2(-) compared to NF2(+) AC-CRISPR clones treated with GSK650394 (2µM, 18h), 
dual mTOC1/2 kinase inhibitor AZD2014 (300 nM, 2h), AktVIII (1 µM, 2h) inhibitors or DMSO alone. As a control for Akt inhibition, 
AktVIII treatment of insulin-stimulated NF2(+) AC-CRISPR clone is shown (right panel). D. Immunoblotting with indicated antibodies 
of NF2(+) and NF2(-) AC-CRISPR clones treated with rapamycin (20nM) or DMSO for 2h (left panel) and 24h (right panel) shows an 
increase in pNDRG1 after rapamycin treatment. 
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CRISPR cells, confirming our previous reports [7, 21] 
that Akt activation is not responsible for constitutive 
mTORC1 activation in NF2 target cell types. These 
data indicate that mTORC1 activation in NF2-null AC-
CRISPR cells, at least in part, is dependent on a novel 
mechanism involving distinct activation of mTORC2-
SGK1 signaling that is independent of mTORC2-Akt 
signaling. Further, we examined whether rapamycin 
was capable of activating mTORC2-SGK1 in our 
cellular model, which is a known concern of rapamycin 
treatment through relieving feedback mechanisms toward 
mTORC2-Akt signaling [18]. Treatment with rapamycin 
for 2h and 24h inhibited mTORC1 signaling as measured 
by decreased pS6, however, mTORC2-SGK1 signaling, 
detected by pNDRG1, concomitantly increased in both the 
NF2-expressing and NF2-null AC-CRISPR cells grown 
under full serum conditions (Figure 5D) confirming that 
mTORC2-SGK1 signaling is activated by rapamycin. 
Taken together, these results suggest that dual inhibition 
of mTORC1 and mTORC2 could be more effective in 
NF2-deficient cells. 
Figure 6: NF2-deficiency leads to increased expression of SGK1. A. and B. Immunoblot of patient-derived NF2-deficient 
primary meningiomas A. and NF2-null (A4, A17 and A19) AC-CRISPR clones B. shows increased SGK1 protein expression compared to 
normal (NF2+) ACs or NF2-expressing (A3) AC clone, respectively. NF2 expression is shown A. and GAPDH serves as a control A. and 
B.. C. Quantitation of real-time RT-PCR of human SGK1 (hSGK1) using 2 independent primer sets (hSGK1 qPCR-1 and hSGK1 qPCR-2) 
shows decreased SGK1 expression in serum-deprived NF2-expressing (A2, SF) AC-CRISPR clone compared to full serum (FS) conditions. 
Furthermore, under serum-deprived conditions (SF), isogenic NF2-null (A4 and A17) clones reveal a statistically significant increase in 
SGK1 expression compared to NF2-expressing (A2) clone. Real-time PCR was carried out in triplicate for each primer set (3 independent 
experiments). Data are presented as mean +/- SD (*p < 0.05, **p < 0.005). FS, full serum conditions; SF, serum-free conditions.
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NF2 loss in human ACs and meningioma cells 
leads to increased expression of SGK1
Activation and expression of SGK1 are tightly 
controlled in response to serum stimulation and 
glucocorticoids, and increased expression is regulated 
at the transcriptional and post-translational levels [29]. 
Further, overexpression of SGK1 has been reported 
in multiple cancers, including breast cancer [30, 31]. 
Therefore we examined whether NF2 loss leads to 
increased expression of SGK1. Immunoblotting of 
4 unrelated patient-derived primary NF2-deficient 
Figure 7: AZD2014 is more effective than rapamycin or FRAX597 in decreasing cell viability in NF2-deficient primary 
meningioma cells. A. Immunoblotting of a patient-derived, NF2-deficient primary meningioma cell line reveal attenuation of pS6K 
(mTORC1 readout) upon treatment with rapamycin (20 and 1000 nM, 1h; lanes 1 and 2) with no change in pAkt or pNDRG1 (mTORC2 
readouts) compared to DMSO alone (lane 3). In contrast, treatment with AZD2014 (3-300 nM, 1h; lanes 4-8) shows dose-dependent 
inhibition of both mTORC1 activity (pS6K) and mTORC2 signaling (pAkt and pNDRG1). S6K, Akt, NDRG1 and GAPDH serve as 
controls. B. and C. Dose-response curves for AZD2014 and rapamycin were determined for NF2-deficient primary (MN521, MN527, 
MN580) and immortalized (Ben-Men-1) meningioma cells lines, as well as primary (AC028) and immortalized arachnoid (AC007) cell 
lines, and dose-response curves for FRAX597 were carried out in NF2-deficient primary (MN320, MN521, MN548) and Ben-Men-1 
meningioma cells lines as indicated. Cells were exposed to increasing concentrations of rapamycin (B, left panel) in a 10 point, 10-fold 
serial dilution series (0 - 25 µM); AZD2014 (B, right panel) in a 10 point, 4-fold serial dilution series (0 - 20µM); or FRAX597 C. in a 10 
point, 5-fold serial dilution series (0 - 25 µM) for 72h. Cell viabilities were assessed using CellTiter-Glo assays and plotted as % relative to 
DMSO controls. Cell viability and IC
50
 measurements were performed in at least three independent experiments with similar results. Data 
are presented as mean +/- SD for 3 replicates/drug dosage point B., or 4 replicates/drug dosage point C.. 
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meningioma (MN) cell lines, as well as 3 NF2-null 
AC-CRISPR clones revealed increased SGK1 levels 
compared to control ACs (Figure 6A and 6B). Next we 
tested SGK1 expression at the transcriptional level using 
2 independent primer sets targeting human SGK1 in 
isogenic NF2-CRISPR ACs. As expected, quantitative 
RT-PCR analysis of the NF2-expressing A2(+) clone 
showed decreased SGK1 expression under serum-deprived 
conditions compared to full-serum conditions (Figure 6C). 
The NF2-expressing A3(+) clone also showed identical 
results (data not shown). Interestingly, under serum-
deprived conditions, NF2-null AC-CRISPR clones A4(-) 
and A17(-) revealed 2.5 - 4 fold increased expression in 
SGK1 compared to A2(+) (Figure 6C). Taken together, our 
results demonstrate that NF2 loss in ACs leads to elevated 
SGK1 expression at the transcriptional level, which may 
partly explain the elevated SGK1/pNDRG1 signaling in 
these cells.
Dual mTORC1/mTORC2 inhibitor AZD2014 
is more effective than rapamycin or FRAX597 
in decreasing cell viability in NF2-deficient 
meningioma cells
We compared the effectiveness of AZD2104 
to rapamycin in blocking activation of mTORC1 and 
mTORC2-SGK1 in WHO grades I and II primary MN 
cell lines lacking NF2 expression under full-serum 
growth conditions. A representative immunoblot of a 
grade II MN is shown in Figure 7A. AZD2014 inhibited 
phosphorylation of p70S6K (pS6K, mTORC1 readout), 
pAkt and SGK1/pNDRG1 (mTORC2 readouts) in a 
dose-dependent manner. AZD2014 efficiently inhibited 
both mTORC1-dependent and mTORC2-dependent 
substrate phosphorylation at 100 nM. As expected, 20 
nM rapamycin inhibited mTORC1-dependent S6K 
phosphorylation, however, failed to inhibit mTORC2-
dependent phosphorylation of NDRG1 even at 10-
fold higher doses (1000 nM) than AZD2014. These 
data suggest that AZD2014 is superior to rapamycin in 
Figure 8: A schematic model for regulation of mTORC1/mTORC2 signaling pathways by NF2/merlin. Schematic shows 
NF2 protein merlin as a negative regulator of RAC1-PAK1 signaling as well as a distinct mTORC2-SGK1 signaling axis independent of 
mTORC2-Akt. Upon loss of NF2, constitutive activation of mTORC2-SGK1 and/or RAC1-PAK1 pathways in turn may lead to aberrant 
mTORC1 activation. Treatment with rapamycin analogs such as RAD001 (mTORC1-specific) or group I PAK inhibitors (FRAX597) 
specifically inhibits mTORC1 signaling, whereas treatment with SGK1 inhibitor (GSK650394) or ATP-competitive mTOR kinase inhibitor 
(AZD2014) downregulates both mTORC2-SGK1 and mTORC1 signaling pathways. Chemical inhibitors are shaded. Dashed lines, 
potential pathways.
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inhibiting mTOR signaling in NF2-deficient MN cells in 
vitro. To test whether growth of NF2-associated MNs may 
be dependent on increased mTORC1/mTORC2 signaling, 
we performed cell viability assays of seven independent 
NF2-deficient primary MN cells in the presence of either 
rapamycin or AZD2014. Data from three independent 
cell lines are shown. Cell viability/proliferation of NF2-
deficient MNs was effectively inhibited by AZD2014 
with IC
50
 values < 100 nM after 72 hours of treatment 
(Figure 7B, right). In contrast, rapamycin treatment was 
not as effective as AZD2014 at suppressing NF2-deficient 
meningioma cell proliferation. Although partial growth 
inhibition was observed with low doses of rapamycin 
(1 nM, Figure 7B, left) no further inhibition of cell 
viability/proliferation was observed with increasing the 
concentrations of rapamycin. These data indicate that 
AZD2014 has a much greater effect at inhibiting cell 
proliferation of NF2-deficient MN cells than rapamycin. 
Cell viability assays were also carried out with the group I 
PAK inhibitor FRAX597, which was effective in blocking 
the viability/proliferation of NF2-deficient human MN 
cells, but at higher concentrations (IC
50
 > 4 µM) that may 
not be suitable for treatment (Figure 7C). 
DISCUSSION
mTOR kinase forms two distinct functional 
complexes, mTORC1 and mTORC2, which signal to 
distinct downstream targets. mTORC1 phosphorylates 
p70S6K and 4EBP1 and is inhibited by rapamycin and its 
analogs such as RAD001 through an allosteric mechanism. 
mTORC2 phosphorylates Akt, PKC-α and SGK1 and 
is inhibited by mTOR kinase inhibitors that are ATP-
competitive, but not by Rapalogs [14, 32]. Others and 
we have previously reported activation of mTORC1 in 
NF2-deficient human cells, leading to clinical trials with 
a rapamycin analog [7, 33]. Employing a high-throughput 
shRNA kinome screening, here we have identified 
candidate kinases that may contribute to the observed 
mTORC1 activation in NF2-deficient meningioma cells. 
In particular, we demonstrate that independent activation 
of SGK1 and PAK1 may be partly responsible for the 
mTORC1 activation in NF2-deficient meningioma cells 
(Figure 8, model). We further show elevated expression of 
SGK1 accompanied by constitutive activation of SGK1 as 
detected by phosphorylation of its specific target NDRG1, 
in human arachnoidal and meningioma cells with NF2 
loss. Our results convincingly show that activation of the 
mTORC2-target SGK1/NDRG1 in human meningioma 
cells is sensitive to AZD2014, but insensitive to 
rapamycin. Treatment of primary meningioma cells with 
the dual mTORC1/mTORC2 inhibitor, AZD2014, leads 
to more profound suppression of cell proliferation when 
compared with rapamycin. Further studies are necessary 
to understand whether cell death mechanisms [34] are 
induced upon treatment with AZD2014. 
 Akt and SGK1 are AGC kinases downstream of 
mTORC2 that share approximately 50% identity [35]. 
Akt is generally considered as the critical effector of PI3K 
signaling, and most work in the cancer field is focused on 
Akt being the important mediator of cell proliferation upon 
PI3K activation. However, similar to Akt, SGK family 
members 1) are activated upon dual phosphorylation 
by PDK1 and mTORC2 in the PI3K pathway, 2) reveal 
overlapping substrate specificity with Akt, and 3) are 
implicated as potential players in malignant transformation 
[36-38]. In addition to Akt, phosphorylation of the SGK1-
specific substrate NDRG1 is considered a reliable marker 
for mTORC2 activation [17, 39]. Interestingly, in NF2-
null AC-CRISPR cells, upon deprivation of serum/growth 
factors, SGK1 is activated while Akt is not activated. 
Further, Akt inhibitor has no effect on either pS6 or 
pNDRG1 (Figure 5C). Taken together, it is likely that a 
distinct mTORC2-SGK1 signaling axis, independent of 
mTORC2-Akt, could be a major driver of proliferation 
in NF2-null AC and MN cells (Figure 8, model). A 
recent study documents increased SGK1 expression in 
a subset of breast cancer cell lines that are resistant to 
Akt inhibition, and treatment of these cells with an ATP-
competitive mTOR kinase inhibitor leads to inhibition of 
SGK1 activation and suppression of proliferation, thus 
highlighting the role of SGK1 activation in breast cancer 
[38]. Further, in glioblastomas with activating mutation in 
EGFR, NF-κB is activated through mTORC2 in an SGK1-
dependent manner that does not require Akt or mTORC1, 
underlying the Akt-independence of this pathway [40]. 
Taken together, it is important to examine the activation 
of SGK1/NDRG1 in addition to Akt when evaluating 
mTORC2 activation. 
While much information is known about the 
regulation of mTORC1, the mechanism by which 
mTORC2 is regulated is poorly understood. We have 
observed constitutive activation of mTORC2-SGK1 in 
NF2-null ACs upon serum/growth factor deprivation, and 
further studies are necessary to understand the mechanism 
of this activation. One possibility is the elevated level 
of several growth factor receptors, including ERBB3, 
observed upon NF2 loss at the plasma membrane [41, 
42] that may feed into and activate the mTOR pathway. It 
is also possible that GRK7, EPHA5, and/or ERBB3 that 
we have identified in the kinome screen (Table 1) may 
play a role upstream of mTORC1/mTORC2, and further 
studies are essential on these and the other validated hits 
from the screen. Our work also raises the question of how 
mTORC2 distinctly activates SGK1 independent of Akt 
under growth factor-deprived conditions in NF2-null cells. 
A physical association between the mTORC2-specific 
component, mSIN1 (mammalian stress-activated protein 
kinase-interacting protein 1) and SGK1 is shown to be 
important for the mTORC2-mediated phosphorylation 
of SGK1 and its activation, which appears to be distinct 
from Akt, since Akt does not bind to mSIN1, raising the 
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possibility that mTORC2 could selectively associate 
with its substrates and regulate specific cellular process 
[43]. Based on the increased expression of SGK1 that we 
observe upon NF2 loss, it is tempting to speculate whether 
enhanced binding between SGK1 and mSIN1 occurs in 
NF2-deficient cells, which could be responsible for the 
selective activation of SGK1. Taken together it is possible 
that upstream signaling that activates an mTORC2-SGK1 
axis may be context-specific and not necessarily shared 
with an mTORC2-Akt axis.
To date, there are no medical therapies that have 
proven efficacious for meningiomas, either sporadic or 
NF2-related. Moreover, there are no relevant genetic 
mouse models for drug testing in meningiomas, especially 
for recurrent or progressive tumors. Nf2 mutant mice 
(Nf2+/-) do not develop schwannomas or meningiomas, and 
selective Cre-mediated excision of Nf2 in arachnoidal cells 
results in development of benign (grade I) meningioma 
in mice [44]. However, only 30% of these mice develop 
intracranial meningiomas, which are microscopic and 
require a prolonged time to appear, thus limiting the use of 
this in vivo model for therapeutic studies. Our earlier work 
in human meningioma cells demonstrating the activation 
of mTORC1 led to clinical trials with rapamycin analogs 
for NF2 and sporadic meningioma patients. Rapamycin is 
merely cytostatic in our cells, consistent with the clinical 
outcome thus far observed with RAD001/everolimus. 
Moreover, rapamycin treatment is known to relieve the 
negative feedback inhibition on IRS-1 [45, 46], Grb10 
[47, 48] as well as other negative regulation of mTORC2 
independent of IRS-1 and Grb10 [49, 50], and thus can 
activate PI3K/Akt and ERK/MAPK prosurvival pathways. 
Similarly, here we have shown that rapamycin treatment 
can also upregulate mTORC2-SGK1 signaling (Figure 
5D). As an AGC kinase family member closely related to 
Akt, SGK1 can also phosphorylate Akt substrates such as 
FOXO3a and BAD and lead to potential survival signals 
[36, 37]. Here we establish that, in addition to mTORC1 
activation, mTORC2-dependent activation of SGK1/
NDRG1 is commonly seen in human meningioma cells, 
which remains unaffected by rapamycin treatment. Our 
studies indicate that the selective mTOR kinase inhibitor 
AZD2014, which targets both mTORC1 and mTORC2, 
is more efficient than mTORC1 inhibitor rapamycin in 
blocking proliferation of primary human meningioma 
cells. Importantly, AZD2014 is currently in use in 
AstraZeneca-sponsored clinical trials as well as other 
ongoing Externally Sponsored Research (ESR) studies 
for patients with many types of cancer [51]. Therefore, 
we believe that there is a timely opportunity for testing 
the ATP-competitive dual mTORC1/mTORC2 inhibitor 
AZD2014, which may offer critical therapeutic advantage 
over rapalogs for recurrent or progressive meningiomas
MATERIALS AND METHODS
Cell lines and reagents
Cell lines included immortalized NF2-deficient 
meningioma Ben-Men-1 [15], immortalized arachnoid 
AC007-hTERT derived from an NF2 patient expressing 
heterozygous level of NF2 [7, 8], primary normal 
arachnoid AC028, and several primary NF2-deficient 
meningioma (MN) lines. Ben-Men-1 cells and AC007-
hTERT were maintained under growth conditions 
described [7, 15], and all primary lines were established 
and maintained as reported [8]. Low passage 293T 
cells for large-scale lentiviral packaging were obtained 
from TRC. Insulin was from Sigma (St. Louis, MO). 
Inhibitor reagents included rapamycin and AktVIII 
(EMD Millipore; Billerica, MA), AZD2014 (provided 
by AstraZeneca; Wilmington, DE), GSK650394 (Tocris; 
Minneapolis, MN), Torin1 (kindly provided by Dr. David 
Sabatini, Whitehead Institute/MIT, Cambridge, MA) 
and FRAX597 (generously given by Dr. Joseph Kissil, 
The Scripps Research Institute, Jupiter, FL). Inhibitor 
treatment times and concentrations are described in figure 
legends. All inhibitors were diluted as per manufacturer’s 
recommendations.
High-throughput shRNA screen
The immunofluorescence-based kinome screen was 
carried out using Ben-Men-1 in a 384-well plate format. 
The entire kinome library, developed by TRC, consisted 
of high titer lentivirus for 6,091 shRNAs, cloned into the 
pLKO-puromycin system, targeting 747 distinct kinases 
that were arrayed on 18 384-well plates (5-10 shRNAs/
kinase). Each library virus plate contained internal 
negative controls including shRNAs targeting irrelevant 
reporter genes (GFP, RFP, luciferase and LacZ), a non-
hairpin forming (nullT) control and media alone (no virus). 
Each screening plate included a positive control lentiviral 
human RHEB-shRNA (TRCN0000010424). In addition, 
a separate library control plate was used consisting of 95 
distinct negative control hairpins. Infections included 4 
biological replicates, 3 under puromycin (puro) selection 
(0.75µg/ml, Life Technologies; Grand Island, NY) and 1 
without puro. All subsequent steps (addition of lentivirus 
to fixation) were carried out by TRC using robotic liquid 
handling. At 18-20h after plating, each shRNA lentivirus 
was transferred onto cells in the presence of 5µg/ml 
polybrene (Sigma). The cells were spun at 2250rpm at 
370C for 30min, and transferred to 370C overnight. The 
following day, virus was removed and fresh growth media 
was added (with or without puro). After 72h, cells were 
incubated in serum free media for 18-20h and fixed in 
4% paraformaldehyde (Electron Microscopy Sciences; 
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Hatfield, PA) at room temperature for 20min. Cells were 
permeabilized and blocked in one step with 0.2% Triton 
X-100/2%BSA/PBS for 20min at room temperature 
followed by co-incubation with AlexaFlour488 
conjugated-pS6 (Ser240/244) antibody (Cell Signaling 
Technology; Beverly, MA) and DAPI (Life Technologies) 
for 18-20h at +4oC. Analysis for pS6 staining intensity 
was performed using the Acumen eX3 laser-scanning 
fluorescence microplate cytometer. Immunofluorescent 
staining in Figure 1 was visualized on a Nikon (Tokyo, 
Japan) Eclipse TE2000-U inverted microscope using the 
EXFO X-Cite 120 fluorescent illumination system. Images 
were acquired with a Nikon DS-QiMc camera and NIS-
Elements BR imaging software. 
Large-scale lentiviral packaging and infection
For large-scale packaging, pLKO-puro-based 
shRNAs targeting human SGK1 (TRCN0000194957), 
human PAK1 (TRCN0000197238), human RHEB 
(TRCN0000010424) as well as pLKO.1-emptyT (nullT) 
control (TRCN0000208001) were obtained from TRC, and 
packaged using TRC methods (http://www.broadinstitute.
org/rnai/public/resources/protocols). For viral infection, 
Ben-Men-1 cells were transduced using lentiviral shRNAs 
for each of the following hairpins: SGK1, PAK1, RHEB, 
nullT control, as well as no virus control. Spin-infection 
was carried out at 2000rpm for 1.5h at 37oC, and then 
cells were transferred to 37oC overnight. The following 
day, cells were passaged to a 15cm plate, followed by puro 
selection (0.5µg/ml) for 3 days with no live cells observed 
in the control without virus. Media was exchanged for 
fresh growth media without puro prior to all further 
experiments.
Immunoblotting and antibodies
SDS-PAGE and immunoblotting were carried out 
as described [7]. Antibodies for phospho-S6 (S240/244), 
S6, phospho-p70 S6K (T389), p70 S6K, phospho-Akt 
(S473), Akt, phospho-NDRG1 (T346), SGK1, phospho-
PAK1 (S144), Pak1, and 4EBP1 were from Cell Signaling 
Technology. Other antibodies included NDRG1 (Abcam; 
Cambridge, MA), Rac1 (BD Biosciences; San Jose, CA), 
GAPDH (EMD Millipore), Rheb (3M6 monoclonal; 
a generous gift from Richard Lamb, University of 
Liverpool, U.K.) and the NF2 polyclonal C26 antibody 
has been described [52].
Generation of isogenic human arachnoidal cell 
lines using CRISPR-Cas9 gene editing
To generate isogenic NF2-expressing and NF2-
deficient human arachnoidal cells (ACs), we used 
the AC007-hTERT cell line (AC cells). AC cells 
were transfected using the basic primary fibroblasts 
Nucleofector kit and the AmaxaNucleofector II (Lonza; 
Walkersville, MD) according to the manufacturer’s 
instructions. Briefly, AC cells were resuspended in 
Nucleofector solution, and then transfected using 
program U-023 with lenti-CRISPR-NF2_sg1 expressing 
a single guide RNA targeting human NF2 exon 8, the 
Cas9 enzyme, and a puro selection cassette (a kind gift 
from the Zhang laboratory at the Broad Institute and 
MIT [28]. Following transfection, cells were re-plated 
sparsely to form single colonies. Single AC-CRISPR 
cell clones were picked and expanded for genomic DNA 
extraction, PCR of human NF2 exon 8, and Sanger 
sequencing to confirm in/del mutations. PCR primers: 
hNF2 ex 8-F, 5’-gggacccagaagtcacaaga-3’; hNF2 ex 8-R, 
5’-tttcattatgcatgcccaga-3’.
RNA isolation, cDNA synthesis and quantitative 
PCR
AC-CRISPR cells were lysed in TRIzol Reagent 
(Life Technologies), rinsed in chloroform, and aqueous 
layer was applied to Qiagen RNeasy kit (Qiagen; Santa 
Clarita, CA) columns followed by RNA purification 
according to manufacturer’s instructions. For cDNA 
synthesis, the Superscript VILO cDNA synthesis kit (Life 
Technologies) was used according to the manufacturer’s 
instructions, and quantitative RT-PCR (q-RT-PCR) was 
carried out in triplicate on a Roche (Indianapolis, IN) 
Lightcycler 480 (software version 1.5.0 SP3) using iQ-
SYBR Green Supermix (Bio-Rad; Hercules, CA). For 
human SGK1, two independent primer sets were used 
including primer set #1 (254bp amplicon): hSGK1 qPCR-
1F, 5’-atgacggtgaaaactgaggct-3’; hSGK1 qPCR-1R, 
5’-gttctccttgcagagtccgaag-3’, which were validated by 
TRC/Broad Institute (primer sequences from PrimerBank, 
http://pga.mgh.harvard.edu/primerbank/index.html) 
and primer set #2 (132bp amplicon): hSGK1 qPCR-
2F, 5’-GCTGAAATAGCCAGTGCCTTGG-3’; hSGK1 
qPCR-2R, 5’-GTTCTCCTTGCAGAGTCCGAAG-3’. 
Human 18S served as a control using primers: h18S-F, 
5’-ACCCGTTGAACCCCATTCGTGA-3’; h18S-R, 
5’-GCCTCACTAAACCATCCAATCGG-3’. Melt curves 
showed single peak specificity for each q-RT-PCR primer 
set.
Statistical analysis
For the high-throughput screen, data acquisition, 
analysis and top hit calling was performed by TRC using 
robust z scoring methodology to normalize data [16]. For 
q-RT-PCR, all experiments were performed in triplicate. 
Fold changes in gene expression were calculated using the 
comparative CT (threshold cycle) method, and expression 
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levels were quantitated relative to control (normalized to 
1.0). Data values are represented as mean +/- SD. Within 
each group, student t-test was performed with a value of p 
< 0.05 considered significant.
Cell viability assays
Cell viability was assessed in 384-well plates using 
CellTiter-Glo Luminescent Cell Viability Assay (Promega; 
Madison, WI). Briefly, the next day after seeding, cells 
were treated with serial dilutions of AZD2014, rapamycin 
or FRAX597 in full growth media and incubated for 72h 
(see figure legends for dilution point details). DMSO was 
used as a control. Luminescence was detected using an 
EnVision Plate Reader (Perkin Elmer; Waltham, MA) 
and mean values +/- SD from at least 3 independent 
experiments were determined for each meningioma cell 
line. Growth curves were plotted using GraphPad Prism 
6.0 software (San Diego, CA) and drug concentrations 
inhibiting cell growth by 50% (IC
50
) was determined using 
nonlinear regression (curve fit) analysis. 
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